vs
GENESIS ENERGY LP（GEL）与INTEGRA LIFESCIENCES HOLDINGS CORP（IART）财务数据对比。点击上方公司名可切换其他公司
GENESIS ENERGY LP的季度营收约是INTEGRA LIFESCIENCES HOLDINGS CORP的1.0倍（$440.8M vs $434.9M），GENESIS ENERGY LP同比增速更快（10.5% vs -1.7%），GENESIS ENERGY LP自由现金流更多（$87.0M vs $-5.4M），过去两年INTEGRA LIFESCIENCES HOLDINGS CORP的营收复合增速更高（8.6% vs 0.7%）
Genesis Energy LP是一家总部位于美国的中游能源合伙企业，主营原油、天然气、成品油及特种工业原料的基础设施运营与物流服务，旗下资产涵盖管道、仓储码头、海运设施及铁路物流枢纽，为北美地区的炼油厂、工业客户及能源分销商提供服务。
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
GEL vs IART — 直观对比
营收规模更大
GEL
是对方的1.0倍
$434.9M
营收增速更快
GEL
高出12.2%
-1.7%
自由现金流更多
GEL
多$92.4M
$-5.4M
两年增速更快
IART
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $440.8M | $434.9M |
| 净利润 | $19.9M | — |
| 毛利率 | — | 50.8% |
| 营业利润率 | 20.4% | 5.3% |
| 净利率 | 4.5% | — |
| 营收同比 | 10.5% | -1.7% |
| 净利润同比 | 140.2% | — |
| 每股收益（稀释后） | $0.04 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GELIART
| Q4 25 | $440.8M | $434.9M | ||
| Q3 25 | $414.0M | $402.1M | ||
| Q2 25 | $377.3M | $415.6M | ||
| Q1 25 | $398.3M | $382.7M | ||
| Q4 24 | $398.9M | $442.6M | ||
| Q3 24 | $397.3M | $380.8M | ||
| Q2 24 | $430.2M | $418.2M | ||
| Q1 24 | $434.4M | $368.9M |
净利润GELIART
| Q4 25 | $19.9M | — | ||
| Q3 25 | $9.2M | $-5.4M | ||
| Q2 25 | $-406.0K | $-484.1M | ||
| Q1 25 | $-469.1M | $-25.3M | ||
| Q4 24 | $-49.4M | — | ||
| Q3 24 | $-17.2M | $-10.7M | ||
| Q2 24 | $-8.7M | $-12.4M | ||
| Q1 24 | $11.4M | $-3.3M |
毛利率GELIART
| Q4 25 | — | 50.8% | ||
| Q3 25 | — | 51.5% | ||
| Q2 25 | — | 50.4% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 56.1% |
营业利润率GELIART
| Q4 25 | 20.4% | 5.3% | ||
| Q3 25 | 19.0% | 2.9% | ||
| Q2 25 | 17.9% | -123.4% | ||
| Q1 25 | 5.5% | -4.0% | ||
| Q4 24 | 3.4% | 8.0% | ||
| Q3 24 | 12.2% | -2.1% | ||
| Q2 24 | 11.6% | -0.7% | ||
| Q1 24 | 13.4% | 1.1% |
净利率GELIART
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.2% | -1.3% | ||
| Q2 25 | -0.1% | -116.5% | ||
| Q1 25 | -117.8% | -6.6% | ||
| Q4 24 | -12.4% | — | ||
| Q3 24 | -4.3% | -2.8% | ||
| Q2 24 | -2.0% | -3.0% | ||
| Q1 24 | 2.6% | -0.9% |
每股收益（稀释后）GELIART
| Q4 25 | $0.04 | $-0.03 | ||
| Q3 25 | $-0.05 | $-0.07 | ||
| Q2 25 | $-0.12 | $-6.31 | ||
| Q1 25 | $-4.06 | $-0.33 | ||
| Q4 24 | $-0.58 | $0.25 | ||
| Q3 24 | $-0.32 | $-0.14 | ||
| Q2 24 | $-0.25 | $-0.16 | ||
| Q1 24 | $-0.09 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.4M | $263.7M |
| 总债务越低越好 | $3.0B | $726.6M |
| 股东权益账面价值 | — | $1.0B |
| 总资产 | $4.9B | $3.6B |
| 负债/权益比越低杠杆越低 | — | 0.70× |
8季度趋势，按日历期对齐
现金及短期投资GELIART
| Q4 25 | $6.4M | $263.7M | ||
| Q3 25 | $4.9M | $267.9M | ||
| Q2 25 | $4.5M | $253.6M | ||
| Q1 25 | $377.4M | $273.3M | ||
| Q4 24 | $7.4M | $273.6M | ||
| Q3 24 | $13.0M | $277.6M | ||
| Q2 24 | $13.7M | $296.9M | ||
| Q1 24 | $7.0M | $663.1M |
总债务GELIART
| Q4 25 | $3.0B | $726.6M | ||
| Q3 25 | $3.1B | $736.3M | ||
| Q2 25 | $3.1B | $745.9M | ||
| Q1 25 | $3.4B | $755.6M | ||
| Q4 24 | $3.7B | $760.5M | ||
| Q3 24 | $4.0B | $765.3M | ||
| Q2 24 | $3.9B | $770.2M | ||
| Q1 24 | $3.8B | $775.0M |
股东权益GELIART
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.6B |
总资产GELIART
| Q4 25 | $4.9B | $3.6B | ||
| Q3 25 | $4.9B | $3.6B | ||
| Q2 25 | $4.8B | $3.7B | ||
| Q1 25 | $5.2B | $4.1B | ||
| Q4 24 | $7.0B | $4.0B | ||
| Q3 24 | $7.1B | $4.1B | ||
| Q2 24 | $7.0B | $4.1B | ||
| Q1 24 | $6.9B | $4.1B |
负债/权益比GELIART
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.71× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 0.49× | ||
| Q3 24 | — | 0.50× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $110.8M | $11.8M |
| 自由现金流经营现金流 - 资本支出 | $87.0M | $-5.4M |
| 自由现金流率自由现金流/营收 | 19.7% | -1.2% |
| 资本支出强度资本支出/营收 | 5.4% | 4.0% |
| 现金转化率经营现金流/净利润 | 5.58× | — |
| 过去12个月自由现金流最近4个季度 | $65.9M | $-31.1M |
8季度趋势，按日历期对齐
经营现金流GELIART
| Q4 25 | $110.8M | $11.8M | ||
| Q3 25 | $70.3M | $40.9M | ||
| Q2 25 | $47.0M | $8.9M | ||
| Q1 25 | $24.8M | $-11.3M | ||
| Q4 24 | $74.0M | $50.7M | ||
| Q3 24 | $87.3M | $22.5M | ||
| Q2 24 | $104.7M | $40.4M | ||
| Q1 24 | $125.9M | $15.8M |
自由现金流GELIART
| Q4 25 | $87.0M | $-5.4M | ||
| Q3 25 | $43.3M | $25.8M | ||
| Q2 25 | $-7.6M | $-11.2M | ||
| Q1 25 | $-56.8M | $-40.2M | ||
| Q4 24 | $-47.1M | $21.1M | ||
| Q3 24 | $-32.3M | $-7.2M | ||
| Q2 24 | $-67.5M | $10.7M | ||
| Q1 24 | $-48.3M | $291.0K |
自由现金流率GELIART
| Q4 25 | 19.7% | -1.2% | ||
| Q3 25 | 10.5% | 6.4% | ||
| Q2 25 | -2.0% | -2.7% | ||
| Q1 25 | -14.3% | -10.5% | ||
| Q4 24 | -11.8% | 4.8% | ||
| Q3 24 | -8.1% | -1.9% | ||
| Q2 24 | -15.7% | 2.6% | ||
| Q1 24 | -11.1% | 0.1% |
资本支出强度GELIART
| Q4 25 | 5.4% | 4.0% | ||
| Q3 25 | 6.5% | 3.8% | ||
| Q2 25 | 14.5% | 4.8% | ||
| Q1 25 | 20.5% | 7.6% | ||
| Q4 24 | 30.3% | 6.7% | ||
| Q3 24 | 30.1% | 7.8% | ||
| Q2 24 | 40.0% | 7.1% | ||
| Q1 24 | 40.1% | 4.2% |
现金转化率GELIART
| Q4 25 | 5.58× | — | ||
| Q3 25 | 7.63× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 11.09× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GEL
| Onshore Facilities And Transportation Revenue | $204.2M | 46% |
| Offshore Pipeline Transportation Revenue | $154.3M | 35% |
| Marine Transportation Revenue | $82.2M | 19% |
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
